{"id":"dfn-15-active","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Somnolence"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DFN-15 contains buprenorphine, a partial mu-opioid receptor agonist, formulated as a sublingual tablet to enable faster absorption and more predictable pharmacokinetics compared to traditional buprenorphine formulations. The partial agonist activity at the mu-opioid receptor provides analgesia while maintaining a lower abuse potential and ceiling effect on respiratory depression compared to full opioid agonists.","oneSentence":"DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:24.107Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain"}]},"trialDetails":[{"nctId":"NCT03009019","phase":"PHASE3","title":"Efficacy, Tolerability, and Safety of DFN-15","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2016-12","conditions":"Migraine Headache","enrollment":631},{"nctId":"NCT03006276","phase":"PHASE3","title":"Efficacy, Tolerability, and Safety Study of DFN-15","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2016-12","conditions":"Migraine Headache","enrollment":622},{"nctId":"NCT03472378","phase":"PHASE2","title":"Can DFN-15 Terminate Migraine With Allodynia?","status":"COMPLETED","sponsor":"Hartford Hospital","startDate":"2018-05-09","conditions":"Migraine With Aura, Migraine Without Aura, Allodynia","enrollment":51},{"nctId":"NCT02472418","phase":"PHASE2","title":"Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2015-06-05","conditions":"Migraine","enrollment":63},{"nctId":"NCT03051685","phase":"PHASE1","title":"Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2015-07-20","conditions":"Healthy","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Celecoxib Oral Solution"],"phase":"phase_3","status":"active","brandName":"DFN-15 Active","genericName":"DFN-15 Active","companyName":"BioDelivery Sciences International","companyId":"biodelivery-sciences-international","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management. Used for Moderate to severe acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}